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Abstract 
Surgical aortic valve replacement (AVR) still remains the treatment of choice in
symptomatic significant aortic stenosis (AS). Due to technical problems,
extensive calcification of the ascending aorta (“porcelain aorta”) is an additional
risk factor for surgery and transapical aortic valve implantation (TAAVI) is likely
to be the only rescue procedure for this group of patients. We describe the case
of an 81-year-old woman with severe AS and “porcelain aorta”, in whom the
only available life-saving intervention was TAAVI.
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Introduction
Surgical aortic valve replacement (AVR) still remains the treatment of
choice in symptomatic patients with significant aortic stenosis (AS).
“Porcelain aorta” in conjunction with critical AS is a very important factor
disqualifying the patient from surgery [1, 2]. The recognition of “porcelain
aorta” occurs in less than a third of cases before valve replacement and
it is often made in the operating room. 
The case report on the application of transcatheter aortic valve
implantation in a patient with unclampable ascending aorta and severe
aortic stenosis is presented below.
Case report
An 81-year-old woman, with AS and “porcelain aorta”, was referred to
the Institute of Cardiology in Warsaw in order to decide whether she could
undergo any interventional treatment. 
Critical AS was diagnosed in 2005 when the patient had been
hospitalized due to exacerbation of heart failure (HF) with orthopnoea
(NYHA class III/IV). In transthoracic echocardiographic (TTE) severe AS was
confirmed, with peak aortic gradient (PAG) – 90 mmHg, mean (MAG) – 57
mmHg, aortic valve area (AVA) – 0.6 cm2 and moderate mitral valve
insufficiency (MI) with good left ventricular ejection function (LVEF). No
significant lesions were found in coronary arteries. Holter-EKG revealed
a single episode of atrial fibrillation (AF). The patient was also diagnosed
Correspondence author: 
Ewa Orłowska-Baranowska
MD, PhD
Institute of Cardiology
Warsaw, Poland
E-mail: eorlowska@ikard.pl
Case report
1Institute of Cardiology, Warsaw, Poland
2Military Institute of Health Service, Warsaw, Poland
Submitted: 7 August 2010
Accepted: 13 December 2010
Arch Med Sci 2011; 7, 3: 528-532
DOI: 10.5114/aoms.2011.23425 
Copyright © 2011 Termedia & BanachArch Med Sci 3, June / 2011 529
TAVI in AS and “porcelain aorta”
with chronic lower limb venous insufficiency
(several episodes of thrombophlebitis in the past –
and put on vitamin K antagonist therapy) and other
comorbidities such as hypothyroidism (after
strumectomy), diabetes mellitus type 2 and
osteoporosis. Surgery was carried out in the Cardio-
Surgical Clinic of the Military Institute of Medicine
in Warsaw on 7 December, 2005. The sternotomy
revealed extensively atherosclerotic and calcified
ascending aorta (“porcelain aorta”), which was the
reason why planned AVR was finally not carried out. 
Since that time the patient has been hos  -
pitalized many times because of decom  pensated
HF. In July 2009 she was referred to our department
to assess whether she could undergo transcatheter
aortic valve implantation (TAVI). She was in NYHA
class III/IV, suffering from significant physical
tolerance impairment (distance < 50 m of slow
walking) and also recurrent episodes of rest
dyspnoea and dizziness during physical effort. The
patient’s activity was limited to walking around 
her flat.
Physical examination showed the features of
pulmonary congestion, AS and MI murmur.
Electrocardiogram showed regular sinus rhythm
(70/min), pathological sinistrogram and slow
progression of R waves in V1-V3 leads. In the chest
X-ray apart from pulmonary congestion and
hypertension, extensive atherosclerotic plaques and
calcifications of the aortic valve and thoracic aorta
were found. Additionally, pulmonary emphysema
and features of osteoporosis were diagnosed.
A TTE confirmed severe AS (tricuspid valve) with
PAG 120 mmHg, MAG 86 mmHg, and AVA 0.6 cm2
and mild to moderate insufficiency of mitral and
tricuspid valve with pulmonary hypertension
(systolic pulmonary artery pressure – SPAP – 
62 mmHg) (Figure 1). The patient was again
disqualified from classical surgical AVR due to
“porcelain aorta”. Moreover, the risk of morbidity
with surgery in the 81-year-old patient with many
comorbidities was estimated as 35.11%. 
The patient was offered TAVI as an alternative
treatment modality and the only possibility of
therapeutic intervention. 
Because of “porcelain aorta” (Figure 2) and the
possibility of damage of the fragile aortic wall with
retrograde (transfemoral) TAVI the only possible way
of replacement of the aortic valve was a transapical
approach (TAAVI). On 8 September, 2009 at the
Cardiac Catheterization Laboratory the transapical
implantation of a 23 mm Edwards-Sapien prosthesis
(Edwards Lifesciences) was carried out in general
anaesthesia and under both angiographic and
transesophageal echocardiogram (TEE) guidance.
The procedure was performed without compli  -
cations by a team of interventional cardio  logists
and surgeons (Figures 3 A, B) [3]. The correctly posi  -
tioned stented bioprosthesis generated a systolic
gradient of 15 mmHg with a small perivalvular leak
immediately after the implan  tation.
The patient stayed in the postoperative room for
two days. No pericardial effusion was found. Systolic
pulmonary artery pressure (SPAP) on the second
day after surgery dropped to 48 mmHg from 
62 mmHg; LVEF on the 10th day after the surgery
was 75%.
The postprocedural period was complicated by
pulmonary congestion and left-sided pleurisy,
effectively treated with diuretics, and recurrent
episodes of AF with a rapid ventricular rate that
receded after giving amiodarone. The patient was
taking triple anticoagulant therapy – clopidogrel,
aspirin and low-molecular-weight heparin – for 
13 days after the procedure. 
The patient, in stable condition, with good
function of circulatory and respiratory systems, was
discharged from the hospital on the 19th day after
TAAVI, with recommendations to continue
anticoagulant therapy with antagonists of vitamin
K and double antiplatelet therapy for 6 months. 
After 3 and 6 months post-procedure a signi  fi  -
cant improvement of the physical tolerance was
observed. The distance after the procedure increased
Figure 1. TTE of patient with severe aortic stenosis.
CW Doppler-peak and mean gradient
Figure 2. Angio-CT scan. Extensive calcification of the
ascending aorta530 Arch Med Sci 3, June / 2011
to 1 km walking on flat ground (from 50 m). The
patient was able to walk up to the second floor and
reported no effort or rest dyspnoea. Life comfort
and the estimate of mood were improved.
Moreover, the patient had to undergo an immediate
appendectomy because of acute appendicitis on 
25 November, 2009 with no complications. 
A physical examination did not show features of
heart failure. A slight systolic murmur was heard
over the aortic valve; there was also a systolic
murmur over the mitral valve.
A control TTE showed normal function of the
aortic Edwards-Sapien bioprosthesis (PAG – 
28 mmHg, MAG – 14 mmHg), with persistent 
mild perivalvular leak and very good LVEF. The
dimensions of the heart cavities were comparable
to those before the procedure. The degree of mitral
and tricuspid valve insufficiency were reduced
(Table I, Figures 4, 5). 
The improvement concerning the estimation of
the clinical symptoms of heart failure remained
a year after the procedure (NYHA II) just as the
echocardiographic parameters. A control TTE
showed correct functioning of the bioprosthesis
(Table I).
Discussion 
Without surgical correction 5-year survival in
symptomatic severe AS is less than 20% [1, 2, 4].
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Figure 4.  TTE after TAVI procedure. CW Doppler- peak
and mean gradient of Edwards-Sapien prosthesis
Figure 5. TTE 2D PLAX Edwards-Sapien prosthesis
Figure 3 A, B. Fluoroscopy. Implantation of Edwards-Sapien prosthesis
TEE 3 months  6 months 1 year
Peak aortic gradient  28 26 21,5
[mmHg]
Mean aortic gradient  14 14 11,7
[mmHg]
LVEF [%] 70 70 70
RVSP [mmHg] 52 58
Table I. Transoesophageal echocardiographic (TEE)
after transapical aortic valve implantation
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Aortic valve replacement still remains the treatment
of choice. The perioperative mortality is low (3%).
However, among elderly people with many
comorbidities and in case of additional surgical
procedures such as coronary artery bypass graft
(CABG) it increases to 15% or more [4]. It is
estimated that over one third of patients with
severe AS are disqualified from AVR mainly because
of advanced age, low LVEF and concomitant
diseases [1, 2].
In the case presented in this paper, the additional
factor strongly influencing the decision to avoid
surgical AVR was advanced atherosclerosis and
extensive calcium incrustation of the thoracic aorta
(“porcelain aorta”), regardless of other comor  -
bidities and advanced age.
“Porcelain aorta” is a risk factor that significantly
worsens the prognosis of surgery due to technical
problems which prolong the duration of surgery and
increase the risk of embolization to the central
nervous system (CNS) (which turns out to be the
major factor disqualifying the patient from surgical
treatment).
A serious dysfunction of the CNS, caused by
cholesterol and calcium microembolism, is observed
in over 10% of patients with advanced athero  sclerosis
of the ascending aorta who underwent CABG [5].
There are a few case reports describing successful
AVR with endarterectomy of the aortic root or the use
of a conduit with a valve prosthesis connecting the
cardiac apex with the descending aorta, worked out
about 32 years ago by Cooley [6-8]. Also several
reports about the “no-touch” technique of CABG
surgery have been published [8, 9]. 
The diagnosis of “porcelain aorta” seems not to
provoke many clinical and financial problems. Chest
X-ray, transthoracic echocardiography or CT scan is
usually sufficient. Nonetheless, it is very often
overlooked (in two thirds of cases) probably
because of the lack of clinical symptoms and many
times “porcelain aorta” seems to be found by
chance, as in the reported case, during the surgery,
in the operating room, despite the importance of
its diagnosis. This situation exposes the patient 
to unfounded and extensive cardio-surgical
intervention and increases unnecessary costs of
diagnostic and interventional procedures. 
Commonly used scales of surgical risk estimation
such as Logistic Euroscore and STS score do not
take into account the issue of “porcelain aorta” as
well as other important risk factors, which disqualify
patients, regardless of other comorbidities, from
cardio-surgical intervention.
Moreover, the advanced atheromatic changes
within the aorta also limit the possibilities of TAVI,
excluding an anterograde approach through the
femoral and subclavian artery. The only procedure
that can save the life of patients with severe AS and
“porcelain aorta” is the TAAVI [3, 10-14].
The first procedure of TAVI was performed in
2002. It remains the alternative method to surgery
for high-risk patients in the still growing patient
population. Usually the procedure is performed in
older patients with many concomitant diseases, in
whom the surgical risk of death is more than 20%
according Logistic EuroSCORE or 10% according to
STS. As in our case, TAVI could be the only possible
procedure to save the patient’s life [10-14].
Both available types of stented bioprosthesis for
transcatheter implantation, Edwards Sapien
(Edwards Lifesciences) and Core Valve (Medtronic),
can be implanted by the retrograde way through
the femoral or subclavian artery; the Edwards-
Sapien prosthesis also with a transapical approach
– the preferred way in peripheral vascular diseases
and/or “porcelain aorta”. The periprocedural death
rate for TAVI is 2% and the 30-day mortality range
from 5% to 15% – roughly half of that predicted for
surgery, depending on the type of the procedure
and on the experience of the operators. A higher
death rate is characteristic for TAAVI because of the
mere procedure and higher-risk patients with many
comorbidities, which usually is reflected by a higher
EuroSCORE [7-10]. The most frequent early
complications (first 30 days) are need of blood
transfusion, injury of aorta and conduction
disturbances that provoke permanent pacemaker
implantation, renal failure and pneumonia. The
percentage of adverse vascular, cardiac and cerebral
incidents, e.g. death, stroke and myocardial
infarction, is about 15%. Transient renal failure,
paroxysmal AF, and longer period of hospitalization
occur frequently with the transapical approach
whereas the risk of neurological complications
concerning this route of implantation is lower (6%)
in comparison with the retrograde, transarterial
approach [10-14].
The results of the long-term follow-up show that
the survival rate after 1 month is 90%, after 1 year
80% and after 2 years 70%. It should be empha  -
sized that during 3-year observation no aortic valve
prosthesis dysfunctions occurred. Infections of the
implanted valve and the need of reimplantation are
very rare and the main adverse event is bleeding
caused by chronic double antiplatelet therapy
recommended for 6 months after the intervention.
The most frequent causes of death in long-term
follow-up are concomitant diseases [10-14].
Taking into considerations that the major causes
of death in TAVI (among the patients who underwent
TAVI) are not related to the procedure itself, and that
the risk of death in classic AVR is prohibitively high
in old patients, with many comorbidities, TAVI and in
particular TAAVI in patients with “porcelain aorta”
and/or peripheral atherosclerosis is an attractive
alternative to a surgical approach. Despite the fact
that in this hybrid procedure a higher risk of death532 Arch Med Sci 3, June / 2011
and complications in comparison to the transarterial
route is expected, it is still the only possible
therapeutic intervention in this patient cohort [10-14].
Nowadays it is well known that porcelain aorta
is one of the main indications for such a procedure,
but we wanted to stress in the presented case
report the difficulties in preoperative evaluation (to
avoid diagnosis made during surgery) and the
possibility to carry out development in medical
science and practice.
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